We have designed and constructed an oncolytic Ad coexpressing antitumor cytokines (IL-12 and GM-CSF) and RLX (oAd/IL12/GM-RLX; online supplementary figure S4A), ultimately aiming to restore antitumor immune functions in the tumor milieu and enhance the intratumoral penetration of the oncolytic Ad, ICIs, and immune cells through ECM degradation. Here, PPP1R3A is linked to neoplasm.